Plasma cell labeling index and β2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma
暂无分享,去创建一个
W. O'Fallon | J. Katzmann | R. Kyle | P. Greipp | J. Lust | T. Witzig | W. O'Fallon | T. Witzig | P. Greipp | J. Lust | R. Kyle | J. Katzmann | W. O'Fallon
[1] B. Klein,et al. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. , 1992, Blood.
[2] M. Jourdan,et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. , 1991, Blood.
[3] A. Whitehead,et al. Heterogeneous modulation of acute-phase-reactant mRNA levels by interleukin-1 beta and interleukin-6 in the human hepatoma cell line PLC/PRF/5. , 1991, The Biochemical journal.
[4] Jack Cuzick,et al. Long‐term prognostic value of serum β2 microglobulin in myelomatosis , 1990 .
[5] C. Corrado,et al. Prognostic factors in multiple myeloma: definition of risk groups in 410 previously untreated patients: a Grupo Argentino de Tratamiento de la Leucemia Aguda study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Bataille,et al. Therapeutic implications of myeloma staging * , 1989, European journal of haematology. Supplementum.
[7] M. Gobbi,et al. Prognostic variables and clinical staging in multiple myeloma. , 1989, Blood.
[8] E. Montserrat,et al. A new prognostic system for multiple myeloma based on easily available parameters , 1989, British journal of haematology.
[9] H. Kronenberg,et al. Serum thymidine kinase as a marker of disease activity in patients with multiple myeloma. , 1989, Australian and New Zealand journal of medicine.
[10] J. S. San Miguel,et al. Prognostic factors and classification in multiple myeloma. , 1989, British Journal of Cancer.
[11] W. O'Fallon,et al. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. , 1988, Blood.
[12] T. Habermann,et al. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. , 1987, Mayo Clinic proceedings.
[13] E. Ascari,et al. Serum Thymidine Kinase and Beta-2 Microglobulin in Monoclonal Gammopathies , 1987, Tumori.
[14] U. Dianzani,et al. Multiple myeloma: biological and clinical significance of bone marrow plasma cell labelling index. , 1987, Haematologica.
[15] B. Barlogie,et al. Beta2 microglobulin in multiple myeloma , 1985, American journal of hematology.
[16] B. Simonsson,et al. Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma , 1985, British journal of haematology.
[17] N. Schmitz,et al. Staging systems for multiple myeloma: a comparison , 1985, British journal of haematology.
[18] W. O'Fallon,et al. Multiple myeloma: significance of plasmablastic subtype in morphological classification. , 1985, Blood.
[19] S. Salmon,et al. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.
[20] R. Kyle. Multiple myeloma. An update on diagnosis and management. , 1990, Acta oncologica.
[21] B. Barlogie,et al. Ploidy and proliferative characteristics in monoclonal gammopathies. , 1982, Blood.